Trial Profile

A Phase II, Randomized, Controlled, Open-Label, Feasibility Trial to Evaluate if a Single or Repeated Dose of Org 36286 (Corifollitropin Alfa) Followed by a Low Daily Dose of Either hCG [human chorionic gonadotropin] or Recombinant FSH [follicle stimulating hormone] [Urofollitropin] Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Chorionic gonadotropin (Primary) ; Corifollitropin alfa (Primary) ; Urofollitropin (Primary)
Indications Infertility
Focus Therapeutic Use
Sponsors Organon; Schering-Plough

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com